Engineered cascade components and cascade complexes
The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides. Also, disclosed are methods for making and using the engineered Class 1 Type I CRISPR-Cas systems of the present invention.
1. A cell comprising:
a first engineered Class 1 Type I CRISPR-Cas effector complex comprising,
a first Cas5 subunit protein and a first Cas7 subunit protein,
a first fusion protein comprising a first Cas8 subunit protein and a first FokI, wherein the N-terminus of the first Cas8 subunit protein or the C-terminus of the first Cas8 subunit protein is covalently connected by a first linker polypeptide to the C-terminus or N-terminus of the first FokI, and wherein the first linker polypeptide has a length of between 10 amino acids and 40 amino acids, and
a first guide polynucleotide comprising a first spacer capable of binding a first nucleic acid target sequence; and
a second engineered Class 1 Type I CRISPR-Cas effector complex comprising,
a second Cas5 subunit protein and a second Cas7 subunit protein,
a second fusion protein comprising a second Cas8 subunit protein and a second FokI, wherein the N-terminus of the second Cas8 subunit protein or the C-terminus of the second Cas8 subunit protein is covalently connected by a second linker polypeptide to the C-terminus or N-terminus of the second FokI, and wherein the second linker polypeptide has a length of between 10 amino acids and 40 amino acids, and
a second guide polynucleotide comprising a second spacer capable of binding a second nucleic acid target sequence;
wherein a protospacer adjacent motif (PAM) of the second nucleic acid target sequence and a PAM of the first nucleic acid target sequence have an interspacer distance of between 20 base pairs and 42 base pairs; and
wherein the cell is outside of a human body.
2. The cell of claim 1 , wherein the first engineered Class 1 Type I CRISPR-Cas effector complex further comprises a first Cas6 subunit protein and the second engineered Class 1 Type I CRISPR-Cas effector complex further comprises a second Cas6 subunit protein.
3. The cell of claim 2 , wherein the first Cas6 subunit protein and the second Cas6 subunit protein comprise identical amino acid sequences.
4. The cell of claim 1 , wherein the first linker polypeptide has a length of between 15 amino acids and 30 amino acids.
5. The cell of claim 1 , wherein the second linker polypeptide has a length of between 15 amino acids and 30 amino acids.
6. The cell of claim 1 , wherein the length of the first linker polypeptide and the second linker polypeptide comprise the same length.
7. The cell of claim 1 , wherein the interspacer distance of the PAM of the second nucleic acid target sequence and the PAM of the first nucleic acid target sequence is between 22 base pairs and 40 base pairs.
8. The cell of claim 1 , wherein the first FokI and the second FokI comprise distinct monomeric subunits capable of associating to form a heterodimer.
9. The cell of claim 1 , wherein the N-terminus of the first Cas8 subunit protein is covalently connected by the first linker polypeptide to the C-terminus of the first FokI.
10. The cell of claim 1 , wherein the N-terminus of the second Cas8 subunit protein is covalently connected by the second linker polypeptide to the C-terminus of the second FokI.
11. The cell of claim 1 , wherein the first Cas5 subunit protein and the second Cas5 subunit protein comprise identical amino acid sequences, the first Cas7 subunit protein and the second Cas7 subunit protein comprise identical amino acid sequences, and the first Cas8 subunit protein and the second Cas8 subunit protein comprise identical amino acid sequences.
12. The cell of claim 1 , wherein the first guide polynucleotide and the second guide polynucleotide each comprise RNA.
13. The cell of claim 1 , further comprising
a first nucleic acid target sequence; and
a second nucleic acid target sequence.
14. The cell of claim 13 , wherein the first nucleic acid target sequence and the second nucleic acid target sequence each comprise double-stranded DNA.
15. The cell of claim 13 , wherein the first nucleic acid target sequence and the second nucleic acid target sequence each comprise genomic DNA.
16. The cell of claim 1 , further comprising
a donor polynucleotide.
17. The cell of claim 1 , wherein the cell comprises a eukaryotic cell.
18. The cell of claim 17 , wherein the eukaryotic cell comprises a human cell.
19. The cell of claim 1 , wherein the cell comprises a stem cell or a progenitor cell.
20. The cell of claim 17 , wherein the eukaryotic cell comprises an induced pluripotent stem cell.